Thoracic mesenchymal malignant tumors and programed cell death ligand‐1 status: Clinicopathologic and prognostic analysis of eight pulmonary sarcomatoid carcinomas and eight malign...

par Kanji Otsubo, Hiroki Sakai, Hiroyuki Kimura, Tomoyuki Miyazawa, Hideki Marushima, Koji Kojima, Naoki Furuya, Masamichi Mineshita, Motohiro Chosokabe, Junki Koike, Hisashi Saji
Publié 2021

Sulforaphane enhances the antitumor response of chimeric antigen receptor T cells by regulating PD-1/PD-L1 pathway

par Chunyi Shen, Zhen Zhang, Yonggui Tian, Feng Li, Lingxiao Zhou, Wenyi Jiang, Li Yang, Bin Zhang, Liping Wang, Yi Zhang
Publié 2021

Expression of B7-H3 Correlates with PD-L1 and Poor Prognosis in Patients with Cervical Cancer [Corrigendum]

par Zhang Q, Zong L, Zhang H, Xie W, Yang F, Sun W, Cui B, Zhang Y
Publié 2021

Clinical significance of programmed death 1 ligand-1 (CD274/PD-L1) and intra-tumoral CD8+ T-cell infiltration in stage II–III colorectal cancer

par Chih-Yang Huang, Shu-Fen Chiang, Tao-Wei Ke, Tsung-Wei Chen, Ying-Shu You, William Tzu-Liang Chen, K. S. Clifford Chao
Publié 2018

Selectively down-regulated PD-L1 by albumin-phenformin nanoparticles mediated mitochondrial dysfunction to stimulate tumor-specific immunological response for enhanced mild-tempera...

par Zaigang Zhou, Ning Jiang, Jiashe Chen, Chunjuan Zheng, Yuanyuan Guo, Ruirong Ye, Ruogu Qi, Jianliang Shen
Publié 2021

Immune checkpoint blockade in the treatment of malignant tumor: current statue and future strategies

par Wenwen Yang, Caining Lei, Shaoming Song, Wutang Jing, Chuanwei Jin, Shiyi Gong, Hongwei Tian, Tiankang Guo
Publié 2021